Elicera in brief
What is immuno-oncology?
CAR T-cell therapy
This section contains links to IPO related documents mostly in Swedish. Should you have any questions please contact us.
End of subscription period Elicera
Publication of issue, prospectus and listing
The Board of Directors statement
The Accountant's statement
The Board of Directors' resolution in respect of issue of units
Terms and Conditions for warrants series TO 1
Annual Report 2020
Podd-interview Finansräven (in Swedish)
Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.
Elicera Therapeutics AB (publ)
World Trade Center Göteborg
Mässans gata 10, floor 7
412 51, Göteborg
+46 (0)70-331 90 51
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our